94 related articles for article (PubMed ID: 17477789)
1. Predicted B-cell epitopes of HER-2 oncoprotein by a bioinformatics method: a clue for breast cancer vaccine development.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(1):137-8. PubMed ID: 17477789
[TBL] [Abstract][Full Text] [Related]
2. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
3. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
4. Finding a T-cell epitope for a melanoma vaccine by an immunomics technique.
Wiwanitkit V
Asian Pac J Cancer Prev; 2006; 7(4):659-60. PubMed ID: 17250448
[TBL] [Abstract][Full Text] [Related]
5. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
6. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
[TBL] [Abstract][Full Text] [Related]
7. Production and Characterization of New Anti-HER2 Monoclonal Antibodies.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):213-21. PubMed ID: 26090600
[TBL] [Abstract][Full Text] [Related]
8. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer.
Baloria U; Akhoon BA; Gupta SK; Sharma S; Verma V
Amino Acids; 2012 Apr; 42(4):1349-60. PubMed ID: 21229277
[TBL] [Abstract][Full Text] [Related]
9. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
10. Predicted epitopes of malarial merozoite surface protein 1 by bioinformatics method: a clue for further vaccine development.
Wiwanitkit V
J Microbiol Immunol Infect; 2009 Feb; 42(1):19-21. PubMed ID: 19424554
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
[TBL] [Abstract][Full Text] [Related]
12. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
13. Preliminary breast cancer vaccine study shows promise.
Bankhead C
J Natl Cancer Inst; 2007 Jun; 99(11):836. PubMed ID: 17551143
[No Abstract] [Full Text] [Related]
14. Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).
Gabrielli F; Salvi R; Garulli C; Kalogris C; Arima S; Tardella L; Monaci P; Pupa SM; Tagliabue E; Montani M; Quaglino E; Stramucci L; Curcio C; Marchini C; Amici A
PLoS One; 2013; 8(3):e58358. PubMed ID: 23555577
[TBL] [Abstract][Full Text] [Related]
15. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
[TBL] [Abstract][Full Text] [Related]
16. Structure-based peptide mimicry of tumor-associated antigens.
Ohtaki A; Kieber-Emmons T; Murali R
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):1-5. PubMed ID: 23600498
[TBL] [Abstract][Full Text] [Related]
17. Predicted epitopes of Lig A of Leptospira interrogans by bioinformatics method: a clue for further vaccine development.
Wiwanitkit V
Vaccine; 2007 Apr; 25(15):2768-70. PubMed ID: 17239493
[TBL] [Abstract][Full Text] [Related]
18. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer vaccines: current research and future prospects.
Cameron DA
Expert Rev Vaccines; 2002 Jun; 1(1):29-34. PubMed ID: 12908510
[TBL] [Abstract][Full Text] [Related]
20. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
